Search clinical trials for: rivaroxaban

Total 535 results

Professor Saad Shakir
Bayer

Completed

An Observational Post-Authorization Safety Specialist Cohort Event Monitoring Study (SCEM) to Monitor the Safety and Utilization of Rivaroxaban (Xarelto®). (ROSE)

Atrial Fibrillation | Deep Vein Thrombosis | Pulmonary Embolism

United Kingdom
David Anderson
Canadian Institutes of Health Research (CIHR)

Completed

Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban to Aspirin Following Total Hip and Knee Arthroplasty (EPCAT II)

Venous Thromboembolism

Canada
Canadian Network for Observational Drug Effect...
Canadian Institutes of Health Research (CIHR); Drug Safety and Effectiveness...

Completed

Direct Oral Anticoagulants and Venous Thromboembolism

Venous Thromboembolism | Major Bleed

Canada
University Hospital, Brest
Bayer

Completed

Blood-sparing During Hip Prosthesis Surgery With Exacyl® in Patients Treated With Rivaroxaban (ESPER)

Blood Loss After a Total Hip Replacement

France
Bayer
Janssen Research & Development, LLC

Completed

Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Rivaroxaban vs. Vitamin k Antagonists

Atrial Fibrillation

Germany
Janssen Research & Development, LLC
Harvard Medical School (HMS and HSDM); Bayer; Duke Clinical Research Institute

Completed

A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome (GEMINI ACS 1)

Acute Coronary Syndrome

United States, France, Poland, Ukraine, Belgium, Spain, Argentina, Bulgaria, Russian Federation, Turkey, Japan, Canada, Netherlands, Korea, Republic of, Brazil, Australia, Hungary, Sweden, Czechia, Denmark
Bayer
Janssen Scientific Affairs, LLC

Completed

Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism) (EinsteinChoice)

Thrombosis | Venous Thrombosis | Thromboembolism | Venous Thromboembolism | Pulmonary Embolism

Belgium, France, China, Switzerland, New Zealand, South Africa, Hungary, United States, Canada, Australia, Netherlands, Spain, Russian Federation, Austria, Mexico, Taiwan, Brazil, Czechia, Denmark, Germany, Israel, Italy, Korea, Republic... and more
University Hospital Inselspital, Berne

Terminated

Comparison of Antithrombotic Treatments After Aortic Valve Replacement. Rivaroxaban: A New Antithrombotic Treatment for Patients With Mechanical Prosthetic Aortic Heart Valve. (CATHAR)

Aortic Valve Disease | Anticoagulants | Heart Valve Prosthesis Implantation

Switzerland
Assistance Publique - Hôpitaux de Paris

Completed

Patent Foramen Ovale Closure or Anticoagulants Versus Antiplatelet Therapy to Prevent Stroke Recurrence (CLOSE)

Ischemic Stroke | Migraine | Patent Foramen Ovale | Atrial Septal Aneurysm

France
St. Joseph's Healthcare Hamilton
Bayer; University of Alberta; The Ottawa Hospital; Hamilton Health Sciences Corporation and other collaborators

Completed

Rivaroxaban for Antiphospholipid Antibody Syndrome (RAPS)

Antiphospholipid Antibody Syndrome

Canada
Ahmed AbdelMoneim Hassan Ali
Beni-Suef University

Unknown

Thromboprophylaxis in Patients Undergoing Orthopedic Surgeries; Comparison Between Rivaroxaban and Enoxaparin

Surgery--Complications | Thromboses, Deep Vein
Sherief Abd-Elsalam

Unknown

Efficacy and Safety of Rivaroxaban in the Management of Acute Non-neoplastic PVT Compensated Cirrhosis

Portal Vein Thrombosis

Egypt
Bayer
Janssen Research & Development, LLC

Completed

Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Asia (XANAP)

Atrial Fibrillation

Indonesia, Korea, Republic of, Malaysia, Singapore, Thailand, Philippines, Taiwan, Hong Kong, India, Pakistan, Vietnam
Bayer
Janssen Research & Development, LLC

Completed

Oral Rivaroxaban in Children With Venous Thrombosis (EINSTEINJunior)

Venous Thrombosis

France, United States, Switzerland, Netherlands, Canada, Germany, Austria, Australia, Israel, Italy
Janssen Scientific Affairs, LLC
Bayer

Completed

A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention (PIONEER AF-PCI)

Atrial Fibrillation | Percutaneous Coronary Intervention

United States, France, Poland, Ukraine, United Kingdom, Belgium, Germany, Taiwan, Argentina, Mexico, Bulgaria, Malaysia, Romania, Russian Federation, South Africa, Turkey, Korea, Republic of, Australia, Canada, Netherlands, Denmark and more
Bayer

Completed

Anticoagulation Preference by AF Patients Study (PRiSMA-AF)

Atrial Fibrillation

Switzerland
Huashan Hospital

Unknown

Study of Prophylactic Effect of Rivaroxaban on Venous Thromboembolism in AECOPD (SUPREME)

Venous Thromboembolism | Acute Exacerbation Copd

China
Zagazig University

Completed

Efficacy and Safety of Rivaroxaban in Acute Non-neoplastic Portal Vein Thrombosis in HCV

Portal Vein Thrombosis
Bayer
Janssen Research & Development, LLC

Completed

Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Latinamerica and EMEA Region (XANTUS-EL)

Atrial Fibrillation

Colombia, Kazakhstan, Mexico, Russian Federation, Argentina, Azerbaijan, Bahrain, Chile, Egypt, Georgia, Jordan, Kenya, Lebanon, Saudi Arabia, United Arab Emirates, Uruguay, Venezuela
Janssen Scientific Affairs, LLC
Bayer

Completed

A Study to Assess the Independent Effects of 4-Factor Prothrombin Complex Concentrate and Tranexamic Acid on Bleeding/Pharmacodynamics in Healthy Participants

Healthy

United States
Bayer
Janssen Research & Development, LLC

Withdrawn

Verification of XAPPORT: a Decision Support App for Physicians Used for Patients Anticoagulated With Rivaroxaban in Terms of Anticoagulation Management in Elective Surgery: Verification Process of Medical Decision Algorithm (VeriXAPPORT)

Atrial Fibrillation | Venous Thromboembolism | Pulmonary Embolism
University Hospital Inselspital, Berne
University of Lausanne Hospitals

Completed

PK of Rivaroxaban in Bariatric Patients - Extension

Prophylaxis of Venous Thromboembolism

Switzerland
Bayer
Janssen Research & Development, LLC

Completed

Real-world Comparative Effectiveness of Rivaroxaban Versus VKA (RIVA-F)

Atrial Fibrillation

United States
Nihon University
Mebix Inc

Unknown

Japanese Registry of Rivaroxaban Effectiveness & Safety for the Prevention of Recurrence in Patients With Deep Vein Thrombosis and Pulmonary Embolism

Deep Vein Thrombosis | Pulmonary Embolism

Japan
Ortho-McNeil Janssen Scientific Affairs, LLC
Bayer

Completed

Switching Drug Therapy for the Prevention of Blood Clot Formation From Enoxaparin to Rivaroxaban After Orthopedic Surgery for Either Total Hip or Total Knee Replacement

Arthritis | Osteoarthritis, Knee | Thromboembolism | Osteoarthritis, Hip

United States
Janssen Scientific Affairs, LLC
Bayer

Completed

A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy (VENTURE-AF)

Atrial Fibrillation

United States, France, United Kingdom, Belgium, Germany
IHF GmbH - Institut für Herzinfarktforschung
OrbusNeich

Withdrawn

COMBO-Stent in Patients on Chronic Anticoagulant Therapy (COSTA) COSTA-Bleed and COSTA-Outcome Trials (COSTA)

Coronary Disease | Stable Angina | Unstable Angina | STEMI | NSTEMI

Germany
Diagnostica Stago

Completed

Validation of Rivaroxaban Assay for US Registration

Patients Receiving Rivaroxaban Treatment

United States
Asan Medical Center
Bayer

Completed

Rivaroxaban Versus Warfarin in Acute Ischemic Stroke With Atrial Fibrillation (TripleAXEL)

Ischemic Stroke | Transient Ischemic Attack

Korea, Republic of
Janssen Research & Development, LLC
Bayer

Completed

A Study to Assess the Effects of 2 Different Prothrombin Complex Concentrates on the Pharmacodynamics of Rivaroxaban in Healthy Adult Volunteers

Healthy

Belgium
Janssen Research & Development, LLC
Bayer

Completed

A Study to Explore the Pharmacodynamic Changes When Transitioning From Rivaroxaban to Warfarin in Healthy Volunteers

Healthy

Belgium
Janssen Research & Development, LLC
Bayer

Completed

A Pharmacokinetics, Pharmacodynamics and Safety Study of Single Dose of Rivaroxaban in Participants With End-Stage Renal Disease (ESRD) on Maintenance Hemodialysis

End-Stage Renal Disease

United States
Janssen Scientific Affairs, LLC
Bayer

Completed

Pharmacokinetics Study of Oral Rivaroxaban in Healthy Participants

Pharmacokinetics | Healthy Participants | Bioavailability

United States
Bayer
Janssen Research & Development, LLC

Completed

Relative Bioavailability of Oral Suspension of Rivaroxaban Compared to Standard Tablet

Biological Availability

Germany
Bayer
Janssen Research & Development, LLC

Completed

Venous Thromboembolism (VTE) Treatment Study in Japanese Pulmonary Embolism (PE) Patients

Pulmonary Embolism

Japan
Bayer
Janssen Research & Development, LLC

Completed

Observational Study to Assess Sociodemographic and Clinical Features of Patients Treated With Rivaroxaban in Routine Clinical Practice of Hematologists, Cardiologists and Internists of Spain (HEROIC)

Atrial Fibrillation

Spain
Bayer
Janssen Research & Development, LLC

Completed

BAY 59-7939 (Xarelto, SPAF), Non Interventional Studies

Atrial Fibrillation

Germany
Bayer
Janssen Research & Development, LLC

Completed

Xarelto Regulatory Post-Marketing Surveillance

Venous Thromboembolism

Korea, Republic of
Bayer
Janssen Research & Development, LLC

Completed

Satisfaction/Quality of Life With Rivaroxaban in DVT (Deep Venous Thrombosis) Indication (SATORI)

Venous Thrombosis

France
Bayer
Janssen Research & Development, LLC

Completed

Xarelto for VTE Prophylaxis After Hip or Knee Arthroplasty (XAMOS)

Venous Thromboembolism

Switzerland, China, Slovakia, France, Germany, Hungary, Korea, Republic of, Singapore, South Africa, Spain, Sweden, Philippines, Australia, Austria, Colombia, Czech Republic, Estonia, Hong Kong, Italy, Latvia, Lebanon, Lithuania, Macedonia... and more
Bayer
Janssen Research & Development, LLC

Completed

Non-interventional Local Study on Prescription Behavior of Anticoagulation Therapy in Secondary Stroke Prevention in Atrial Fibrillation Patients (NEURO-XAR)

Stroke | Embolism

Russian Federation
Bayer
Janssen Research & Development, LLC

Completed

Russian Non-Interventional Study on Compliance of Venous Thromboembolism (VTE) (SOPRANO)

Arthroplasty, Replacement, Knee | Arthroplasty, Replacement, Hip

Russian Federation
Bayer
Janssen Research & Development, LLC

Completed

Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy (XALIA)

Venous Thrombosis | Deep Vein Thrombosis

Switzerland, France, Germany, Hungary, Spain, Sweden, Austria, Czech Republic, Italy, Moldova, Republic of, Slovenia, Ukraine, United Kingdom, Israel, Portugal, Belgium, Denmark, Greece, Netherlands, Canada, Norway
Bayer
Janssen Research & Development, LLC

Completed

Dose-confirmatory Bridging Study in Total Hip Replacement

Venous Thromboembolism

Japan
Bayer
Janssen Scientific Affairs, LLC

Completed

Belgian Real Life Non-interventional Study (NIS) in Patients Treated With Xarelto Following an Acute Deep Vein Thrombosis (DVT) (BOX-DVT)

Venous Thrombosis

Belgium
Bayer
Janssen Scientific Affairs, LLC

Completed

Belgian Real Life Non-interventional Study (NIS) on Xarelto in Non-valvular Atrial Fibrillation (AF) Patients Treated for the Prevention of Stroke and Systemic Embolism (BOX-AF)

Atrial Fibrillation

Belgium
Bayer
Janssen Scientific Affairs, LLC

Completed

Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients

Deep Vein Thrombosis

Japan
Bayer
Janssen Scientific Affairs, LLC

Completed

Satisfaction/Quality of Life With Rivaroxaban in SPAF (Stroke Prevention in Atrial Fibrillation) Indication (SAFARI)

Atrial Fibrillation

France
Bayer
Janssen Scientific Affairs, LLC

Completed

Dose-confirmatory Bridging Study in Total Knee Replacement

Venous Thromboembolism

Japan
Seoul National University Hospital
Korean Society of Hematology Thrombosis Working Party

Completed

Rivaroxaban for the Prevention of Venous Thromboembolism in Asian Patients With Cancer

Recurrence | Bleeding | Cancer-associated Thrombosis | Rivaroxaban

Korea, Republic of

Search clinical trials for: rivaroxaban

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Czech Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations